United States 
Deutschland 
UK & Ireland Active clinical trials
Common & plantar warts
-
6 US sites: Chicago (Dr Bhatia), Nashville (Dr Gold), Miami (Dr Waibel), Tampa (Dr Tharp), Palm Harbor (Dr Tharp), Chicago (Dr Fleischer)
-
Approximately 124 patients, randomised to Microwave TX (5-10W, 2-3sec, 3-5 times) vs. cryotherapy (5-10 seconds liquid nitrogen spray, 2 cycles separated by complete thaw)
Primary Endpoint
-
Clearance of all treated warts at 3 months past final TX
Secondary Endpoints
-
Clearance of all treated warts using photographs (3, 6 and 12 months)
-
Clearance by the number of warts treated (3 months)
-
Change from baseline for size of treated warts post final treatment (3, 6 and 12 months)
-
Pain score (3, 6 and 12 months)
-
Clearance of all treated warts (6 and 12 months)
-
Reoccurrence (6 and 12 months)
-
Resolution rate (3 months)
-
Patient satisfaction (6 and 12 months)
-
Adverse events
See clinicaltrials.gov for further information: NCT05371834
Actinic keratosis
-
2 sites (Germany and US): Wuppertal (Prof Dirschka), Miami (Dr Waibel)
-
Approximately 60 patients, randomised to microwave treatment on half of their mapped AK lesions
- 3-4W, 3 seconds, 3 times with a 20 second gap
Primary Endpoint
-
Clearance of ≥ 75% treated AK at 2 months after the first TX
Secondary Endpoints
-
Clearance of ≥ 75% treated AK (4 and 6 months)
-
Proportion of subjects with clearance of all AK study lesions (2, 4 and 6 months)
-
Percentage of AK study lesions cleared (2, 4 and 6 months)
-
Pain score during and after treatment
-
Reoccurance (6 and 12 months)
-
Cosmetic outcomes of treated versus untreated AK lesions (2, 4 and 6 months)
-
Adverse events
-
Patient satisfaction
See clinicaltrials.gov for further information: NCT05636800
Fungal nail
- 1 Canadian site: London, Ontario (Dr Gupta)
- 45 patients
- Randomised to microwave therapy at three different time intervals: 7-9W, 1 sec, 5 times
Primary Endpoints
-
Safety of the three treatment regimens (up to 6 months)
-
'FDA efficacy' = temporary increase in clear nail at 3 and 6 months
Secondary Endpoints
-
Safety of the three treatment regimens beyond 6 months
-
Increase in nail clearance (6 months)
-
Mycological cure (6, 9 and 12 months)
-
Effective cure (6, 9 and 12 months)
-
Patient satisfaction
See clinicaltrials.gov for further information: NCT05674747
https://clinicaltrials.gov/study/NCT05674747?intr=swift%20microwave&rank=3